H. Lee Moffitt Cancer Center & Research Institute Home Español About Moffitt Careers Login Search Moffitt.org Search: Patients & Families Researchers Medical Professionals Affiliates Giving About Moffitt > Overview of Moffitt About Moffitt Overview of Moffitt Affiliations & Designations Annual Report Awards & Honors Cancer Answers Careers At Moffitt Contact Us Directions to Moffitt Diversity at Moffitt Headline MCC International Relations Moffitt Campus Moffitt Leadership Moffitt Total Cancer Care Our Story Pressroom Publications Speak Out for Moffitt Tobacco Free Initiative Volunteers   Print This Page   E-Mail This Document Cutaneous T-cell Lymphoma L. Frank Glass, MD;  Karen L. Keller, MD;  Jane L. Messina, MD; John Dalton, MD; Cynthia Yag-Howard, MD; and Neil A. Fenske, MD The diagnosis and treatment of cutaneous T-cell lymphoma are challenging due to the many clinical and histopathologic presentations of the disease. Background:  Cutaneous T-cell lymphoma (CTCL) represents a spectrum of diseases composed of malignant helper T lymphocytes. An accurate diagnosis of early CTCL is difficult because of the varied clinical and histologic expressions of the disease. Methods:  The authors review the epidemiology, possible risk factors, clinical manifestations, diagnostic techniques, staging, prognosis, and treatment options for CTCL. Results:  The varied and often nonspecific clinical and histologic presentations of CTCL may delay diagnosis and staging, thus necessitating further studies such as immunophenotyping, flow cytometry, and T-cell receptor gene rearrangement analysis. Conclusions:  A multidisciplinary approach to the diagnosis, staging, and treatment of CTCL assists in optimizing outcomes from management of patients with this disease. Introduction     Cutaneous T-cell lymphoma (CTCL) is generally classified as a type of non-Hodgkin’s lymphoma, and it represents a spectrum of diseases composed of malignant clonal helper T lymphocytes of the CD4 phenotype. CTCL is the most common type of primary cutaneous lymphoma, representing 65% of cases of skin lymphoma. Widely known variants include Sezary syndrome, Woringer-Kolopp disease (pagetoid reticulosis), CD8+ (suppressor) T-cell lymphoma, granulomatous slack skin, peripheral T-cell lymphoma, angiocentric lymphoma, adult T-cell leukemia/lymphoma, CD30+ (Ki-1+) large-cell or anaplastic lymphoma, and lymphomatoid granulomatosis. Poikiloderma atrophicans vasculare, small and large plaque parapsoriasis, alopecia mucinosa, and lymphomatoid papulosis likely represent early forms of CTCL, but considerable debate still exists as to whether these represent CTCL or separate "premalignant" entities. Accurate diagnosis of early CTCL is difficult because of the varied clinical and histologic expressions of the disease and because of a lack of uniformity regarding diagnosis and treatment.     Issues in CTCL such as epidemiology, possible risk factors, clinical manifestations, diagnosis, staging, and treatment are summarized, with a special emphasis on a multidisciplinary approach in management based on staging information. Epidemiology     The incidence of CTCL has increased from 0.19 cases per 100,000 in 1973 to 0.42 cases per 100,000 in 1984.1 CTCL is approximately twice as common in men as in women, while blacks have twice the incidence of whites. Most cases are diagnosed in the fifth and sixth decades (median age: 50 to 55 years). The course of CTCL is often unpredictable. Mycosis fungoides usually demonstrates epidermotropism by involving the skin first but, with time, it may spread to lymph nodes, blood, and viscera. Survival ranges from only a few months to several decades, depending on the stage of the disease. Most patients experience a prolonged survival with little morbidity, while some patients develop a fulminant course with rapid dissemination and death. The diagnosis and treatment of CTCL may be delayed for years and occasionally decades, thereby increasing the risk of severe morbidity and mortality. Etiology     The term "mycosis fungoides" was initially used by Alibert2 in 1806 to describe a skin eruption that developed into tumors shaped like mushrooms. Mycosis fungoides is a misnomer because there is no association with a fungus.2 Several theories of the etiology of CTCL have been postulated, including exposure to environmental, genetic, and infectious agents. Early epidemiologic studies suggesting a causative role of environmental exposure to chronic antigenic stimulation (eg, industrial chemicals, metals, and herbicides/pesticides) have not been substantiated by recent case-control studies.3,4     At the forefront of etiologic research has been the hypothesis of a retroviral cause of CTCL. The human T-cell lymphotropic virus type-1 (HTLV-1) was found to have a causal relation to adult T-cell leukemia/lymphoma. However, most CTCL patients are negative for the virus, and the known HTLV-1 epidemiologic patterns have not been observed in CTCL. Nevertheless, HTLV-1-like retroviral particles have been found in Langerhans cells, B lymphocytes, and the blood of some CTCL patients, and thus the role of retroviruses in CTCL remains uncertain.5,6 Some groups have found serologic evidence of the Epstein-Barr virus in CTCL patients, suggesting a possible role in the pathogenesis.7,8 Other implicated risk factors include genetic predisposition, radiation exposure, and pre-existing malignancies, although there are little supporting data.9 There is some evidence to suggest immunosuppression as a risk factor for CTCL, including cases of documented CTCL arising in patients infected with the human immunodeficiency virus,10 in organ transplant patients,11 and in treated lymphoma patients.12 Clinical Manifestations     Three classical cutaneous phases of CTCL -- patches, infiltrated plaques, and tumors -- were described by Bazin13 in 1876. The disease may progress through each of these phases, which frequently overlap or occur simultaneously. In 5% to 10% of cases, the tumor phase may be the initial disease presentation without evolution, originally termed the "d’emblee" variant by Videl and Brocq14 in 1885.     Early skin lesions may mimic eczema or papulosquamous eruptions such as tinea corporis, secondary syphilis, or psoriasis. Most investigators believe that large-plaque parapsoriasis represents an early form of CTCL, although this theory remains controversial.15-17 Sequential biopsies of such lesions may be necessary to establish or confirm a diagnosis of CTCL.     Patch-stage lesions are erythematous patches or slightly raised plaques with a fine scale. The lesions may be single or multiple and are often located on the buttocks, thighs, and abdomen (Fig 1). Patch lesions may be intensely pruritic or entirely asymptomatic. "Poikiloderma atrophicans vasculare" is a term used to describe patch lesions with cigarette paper–like atrophy, telangiectasia, and mottled hyperpigmentation.     Plaques of mycosis fungoides are elevated due to epidermal hyperplasia or significant neoplastic lymphocytic infiltrate (Fig 2).  These lesions may develop from pre-existing patches or de novo. They are usually red-brown and sharply demarcated, but they may coalesce to form annular, arciform, or serpiginous patterns, sometimes with central clearing. Infiltrative plaques occurring on the face may result in leonine facies, and those appearing in hairy areas may produce alopecia or cysts. Erythroderma (exfoliative dermatitis) may occur as a result of diffuse infiltration of the skin by neoplastic cells with or without scale.     Tumor-stage CTCL may arise from patches, from plaques, or de novo. Lesions are typically violaceous, exophytic, mushroom-shaped tumors that preferentially affect the face and body folds (Fig 3).18  Lesions often undergo ulceration or necrosis and secondary infection. Pruritus may decrease in intensity during this stage. Over 50% of deaths from CTCL are caused by Staphylococcus aureus or Pseudomonas aeruginosa sepsis. Tumors may undergo transformation into a CD30+ (Ki-1+) large-cell anaplastic variant of CTCL with aggressive biological behavior. Transformation has been reported to range between 8% and 55% of tumor CTCL.19-21 In contrast to the primary Ki-1+ large-cell lymphomas that generally have a good prognosis, the prognosis for secondary Ki-l+ lymphomas developing in association with CTCL is extremely poor.22     Sezary syndrome accounts for approximately 5% of new cases of CTCL and represents the leukemic variant of CTCL. Sezary syndrome is recognized by the classic triad of generalized erythroderma, leukemia, and lymphadenopathy.23,24 Malignant T cells with hyperconvoluted cerebriform nuclei circulate in the blood, whereas epidermotropic properties have been lost. Sezary cells can be detected in the peripheral blood in 90% of erythrodermic CTCL patients.25     The definition of Sezary syndrome based on the number of circulating atypical lymphocytes remains controversial. Some researchers have arbitrarily used cutoffs of 5%, 9%, and 10% of the total leukocyte count as an indicator of the disease.26 An absolute count of 1,000 Sezary cells/mm3 as diagnostic has been suggested by others.27 Nevertheless, as the disease progresses, the ratio of CD4 (T helper) to CD8 (T suppressor) becomes elevated by an expansion of the malignant CD4 clonal population in Sezary syndrome, as well as a decrease in the normal CD4 and CD8 populations. Circulating Sezary cells have also been found in up to 20% of plaque or tumor-stage CTCL, as well as in several benign dermatologic conditions.28 A CD4:CD8 ratio above 5 and nuclear contour indexing using electron microscopy are more sensitive indicators of the quantity of circulating Sezary cell than light microscopy.29,30 Despite the continued uncertainty over the extent of peripheral blood involvement, widespread pruritic erythroderma is the major clinical manifestation of Sezary syndrome. Patients may have fever, chills, weight loss, and malaise. Other features may include hepatomegaly, onychodystrophy, leonine facies, ectropion, alopecia, and palmar-plantar keratoderma. Diagnosis     The diagnosis of CTCL is usually made by recognizing the characteristic clinical manifestations of the disease plus routine histology. In difficult cases, a preliminary diagnosis may be supported by additional laboratory tests such as immunophenotyping, flow cytometry, and T-cell receptor (TCR) gene rearrangement analysis. Light microscopy of hematoxylin and eosin-stained sections from involved skin is still the diagnostic gold standard, but the diagnosis in early stages may be difficult. It takes two to 10 years to diagnose mycosis fungoides since some cases initially resemble other chronic inflammatory dermatoses.31 Frequently, sequential biopsies are necessary before the diagnosis is made. In the prototypical plaque stage, the histologic picture is often diagnostic. Histology reveals a band-like or lichenoid infiltrate of mononuclear cells within the papillary dermis with overlying epidermotropism. These lymphocytes may be found singly or in collections within the epidermis, often surrounded by a clear halo (Pautrier microabscesses) (Fig 4).  High-power examination of mononuclear cells reveals hyperchromatic and irregular nuclear contours (Fig 5).  The epidermis frequently shows a pattern of psoriasiform epidermal hyperplasia with hyperkeratosis and focal parakeratosis.     TCR gene rearrangement (TCRGR) analysis, using Southern blot or polymerase chain reaction (PCR) methods, helps to confirm early or atypical CTCL when the histology is suggestive but not diagnostic.32 TCRGR analysis is well established as a determinant of clonality within lymphoid populations. The TCR is a glycoprotein with four subunits (alpha, beta, gamma, and delta). In normal peripheral blood T lymphocytes, the TCR genes are composed of 90% to 98% alpha/beta subunits. During the process of antigen recognition, the beta subunit undergoes TCRGR and, as a result, each T cell produces a singly unique TCR gene. A polyclonal population of T cells produces a variety of TCR gene products. In contrast, the T-cell expansion population in CTCL is monoclonal as multiple copies of the same TCRGR are produced by identical daughter cells. The cells may be detected by Southern blot analysis (DNA hybridization) or PCR if found in large enough quantities.     Most reported cases of CTCL have a clonal rearrangement detected by TCRGR analysis. The diagnostic value of TCRGR analysis by Southern blot is limited by a low sensitivity, since a level of abnormal T-cell clone infiltration below 5% may be too low for detection. PCR has a sensitivity that is 105 times greater than Southern blotting, and the increase in the limit of detection may allow a diagnosis of CTCL in very early disease stages.33,34     The PCR method for detection of TCRGR is a promising diagnostic technique. Further advances in our knowledge of clonality in CTCL are necessary before PCR can be used as a sole diagnostic test for CTCL. For example, some nonneoplastic T-cell disorders such as pityriasis lichenoides et varioliformis acuta may display some level of clonality.21     Further clinical evaluation of CTCL patients includes a complete history and physical examination, emphasizing the types of skin lesions, body surface area, lymph node, liver, and spleen involvement. Baseline tests should include a complete blood cell count, peripheral blood flow cytometry for T-cell subsets, serum chemistries (liver and renal function tests, calcium, phosphorus, uric acid, lactate dehydrogenase), chest radiograph, and biopsy or fine-needle aspiration of palpable lymph nodes. Additional staging procedures for patients with advanced disease include computed tomography scan of the abdomen and pelvis, gallium scan, and bone marrow biopsy. Staging and Prognosis     A number of staging systems for CTCL have been proposed. The simplest and most widely used system, adopted by Lamberg et al,35 incorporates the tumor-node-metastasis (TNM) system. This staging system combines both clinical and histopathologic perspectives (Table). Patients can be divided into three prognostic groups at initial presentation36: (1) good-risk patients with patch or plaque skin lesions without lymph node, blood, or visceral involvement (median survival = 12 years), (2) intermediate-risk patients with plaques, tumors, or erythroderma with lymph node and or blood involvement but no visceral disease (median survival = 5 years), and (3) poor-risk patients with visceral involvement or complete lymph node effacement (median survival = 2.5 years).     Another classification based on lymph node involvement is the LN system, used to define prognosis once the diagnosis of CTCL has been established in the skin. In this system, LN1 nodes have single infrequent atypical lymphocytes in paracortical T-cell regions, LN2 nodes have small clusters of paracortical atypical cells, LN3 nodes have large clusters of atypical cells, and LN4 nodes are partially or totally effaced by atypical cells. The LN classification directly correlates with disease progression as well as with survival and prognosis. Detection of the TCR rearrangement in lymph nodes is associated with an inferior survival rate regardless of the LN class. Therefore, the LN classification is helpful in detecting patients with lymph node involvement who may benefit from more aggressive therapy.37 Treatment     Treatment regimens in CTCL include skin-directed therapies such as psoralen with UVA irradiation (PUVA), topical chemotherapy with mechlorethamine (nitrogen mustard) and carmustine (BCNU), and electron beam radiation, as well as systemic therapies such as chemotherapy, photopheresis, and interferons. A stage-adapted approach to CTCL therapy is used most often.     Currently, a conservative approach using topical therapy is the preferred first-line treatment for early-stage CTCL.38 A recent randomized study39 failed to show a survival benefit in patients with CTCL using aggressive combination chemotherapy and radiotherapy. For minimally perceptible lesions that are clinically and/or histopathologically suggestive of CTCL (stage 0), a trial of glucocorticoids is indicated and has been shown to induce clinical remission in early CTCL.39 If there is no response to glucocorticoids, oral PUVA is most commonly used, although some patients may respond to UVB therapy.      Topical nitrogen mustard (mechlorethamine) is an alternative topical therapy for minimal disease burdens and sites that are unresponsive or difficult to reach with PUVA. Topical nitrogen mustard induces a complete remission rate of approximately 30% to 60%, with better results in early than advanced disease.40 Mechlorethamine can be applied as an aqueous solution that is prepared by dissolving the contents of a 10-mg vial in 50 mL of water, or it can be compounded as an ointment. Side effects of mechlorethamine include allergic and irritant contact dermatitis, pruritus, and hyperpigmentation.40 Hypersensitivity reactions to the topical solution may develop in 35% to 58% of patients.41,42 An immediate-type hypersensitivity reaction with urticarial lesions may also occur in up to 8% of patients.43 Unlike delayed hypersensitivity reactions where desensitization may be used to continue with therapy, patients who develop immediate hypersensitivity reactions must terminate therapy to avoid a potentially life-threatening anaphylactic reaction. Ointment-based mechlorethamine has been used since 1982, and the response, survival, and relapse rates are similar for both the aqueous solution and the ointment. However, the incidence of hypersensitivity reactions is significantly less with the ointment than with the solution. The frequency of delayed hypersensitivity reactions to the solution was only 8% in patients with a history of allergy to mechlorethamine and 0% in patients being initially exposed to the ointment.44,45 In addition, the ointment remains stable for at least 40 days at 37 degrees Celsius and 80 days when refrigerated at 4 degrees Celsius. In contrast, the same concentration of aqueous solution is fully degraded after only four days.46      Treatment of CTCL by PUVA was described by Gilchrest et al47 in 1976 and is considered the initial treatment for stage I through IIa disease. PUVA is effective in clearing early-stage CTCL and in prolonging remission with maintenance therapy.48-50 In a study of 82 patients with a mean follow-up of 45 months,51 complete clearing of lesions was shown in 88% with limited plaque disease and in 51.9% with extensive plaque disease. The mean duration of remission was 13 months for patients with limited plaque disease and 11 months for patients with extensive plaque disease. PUVA is generally well tolerated; few side effects such as erythema, nausea, and pruritus occur in 10% to 20% of patients.51-53 If patients have an inadequate response to PUVA, then combination therapy with retinoids-PUVA or interferon (IFN)-PUVA should be considered.54 If there is no clinical response to these measures, total-skin electron-beam (TSEB) therapy may be instituted. An 84% complete response rate and a 10-year survival rate of 46% have been reported.55 Because of the high rate of relapse with TSEB, adjuvant maintenance therapy with PUVA alone or combined with low-dose oral methotrexate or IFN-alfa is recommended.55,56 Side effects associated with radiation therapy include xerosis, erythema, telangiectasia, extremity edema, and alopecia.57     Radiation therapy is the treatment of choice for patients with tumor-stage (stage lIb) CTCL. With local-field electron beam radiation, 71% of tumor-stage patients achieved a complete remission over a five-year period.58 After completion of local-field electron beam therapy, PUVA maintenance is recommended. If there is no response, patients require treatment according to stage IV guidelines. Patients with patches, plaques, and nodules who have responded to PUVA in the past may be treated with PUVA in conjunction with local radiation. If there has not been a prior response, patients should receive TSEB radiation. Classification Description     T: Skin   T0 Lesions clinically and/or histopathologically suggestive of CTCL T1 Limited plaques, papules, or eczematous patches covering <10% of skin surface T2 Generalized plaques, papules, or erythematous patches covering >=10% of skin surface T3 Cutaneous tumors T4 Generalized erythroderma     N: Lymph nodes   N0 No palpable lymphadenopathy, lymph node pathology negative for CTCL N1 Palpable lymphadenopathy; lymph node pathology negative for CTCL N2 No palpable lymphadenopathy, lymph node pathology positive for CTCL N3 Palpable lymphadenopathy, lymph node pathology positive for CTCL     B: Blood   B0 Atypical circulating cells not present (<5%) B1 Atypical circulating cells present (>=5%)     M: Viscera   M0 No visceral organ involvement M1 Visceral organ involvement, pathology present Stage T N M         Ia 1 0 0 Ib 2 0 0 IIa 1-2 1 0 IIb 3 0-1 0 III 4 0-1 0 IVa 1-4 2-3 0 IVb 1-4 0-3 1 Adapted from Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep. 1979;63:725-728. Staging of Cutaneous T-cell Lymphoma: TNM Classification

    The treatment of choice for patients with erythrodermic disease (stage III) is photopheresis, which was first described as a treatment for CTCL by Edelson⁵⁹ in 1987. Photopheresis involves the removal of leukocytes by leukopheresis after ingestion of 8-methoxypsoralen (8-MOP). The ex vivo cells are exposed to UV light and then reinfused into the patient. Although the exact mechanism is not fully elucidated, the resultant alteration of cell-surface antigens is thought to stimulate a host response. The majority of patients show complete clearance or >50% improvement with therapy^59-61 and a prolonged survival compared with historical control groups.⁶² Photopheresis can achieve a significant improvement in quality of life with minimal side effects. The most frequently reported side effect is transient nausea from the psoralen.

    If there is no response to photopheresis alone for stage III disease, low-dose IFN or low-dose oral methotrexate may be added. The three classes of IFNs (alpha, beta, and gamma) exhibit antiviral, antiproliferative, and immunomodulatory effects.⁶³ The most commonly used IFN for the treatment of CTCL is IFN-alfa, subtype 2a. The first use of systemic IFN-alfa-2a for CTCL was first reported by Foon and Bunn in 1986.⁶⁴ The optimal dose of IFN has yet to be determined. Kohn et al⁶⁵ studied the use of intermittent high-dose IFN-alfa-2a therapy in 24 patients with advanced CTCL who had failed at least one previous treatment. Complete response was seen in 4% of patients, while a partial response was achieved in 25% of patients. Side effects of IFN-alfa-2a include fever, chills, lethargy, hepatotoxicity, leukopenia, and a reversible nephrotic syndrome.⁶⁶

    The first-line treatment for patients with refractory disease or extracutaneous involvement (stage IVa or b) is single or multi-agent chemotherapy. Methotrexate may be administered in high intravenous dosages. The purine analogues such as 2-chlorodeoxyadenosine, fludarabine, and pentostatin have demonstrated promising clinical results in refractory CTCL.⁶⁷ EPOCH, a combination of etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, is reserved for patients with resistant, extensive, or advanced CTCL. With combination chemotherapy, responses may be seen in approximately 80% of patients and complete remission in 38% of patients.⁶⁸ DAB IL-2 is the product of the fusion of the IL-2 gene with a portion of the diphtheria toxin gene. The resulting chimeric protein selectively targets cells with a high number of IL-2 receptors. Other toxins such as ricin have been used instead of the diphtheria toxin. This method of treatment remains experimental and is being administered only within clinical trials. There is no widely accepted standard combination therapy for CTCL, but chemotherapy may be used with TSEB radiation with or without IFN. PUVA may supplement chemotherapy to reduce tumor cell burden. Photopheresis is recommended as an adjuvant to chemotherapy if large numbers of circulating Sezary cells are present. If intensive chemotherapy is used, however, the resultant immunosuppression may negate the activity of PUVA or photopheresis.

Conclusions

References

1. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA. 1988;260:42-46.

2. Alibert JLM. Description des Maladies de la Peau Observees a l’Hopital St. Louis. Barrois L’aine et Fils. 1806:413-446.

3. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst. 1989;81:1560-1567.

4. Tuyp E, Burgoyne A, Aitchison T, et al. A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol. 1987;123:196-200.

5. Zucker-Franklin D, Pancake BA. The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas. Semin Dermatol. 1994;13:160-165.

6. Lessin SR, Vowels BR, Rook AH. Retroviruses and cutaneous T- cell lymphoma. Dermatol Clin. 1994;12:243-253.

7. Lee PY, Charley M, Tharp M, et al. Possible role of Epstein-Barr virus infection in cutaneous T-cell lymphomas. J Invest Dermatol. 1990;95:309-312.

8. Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733-741.

9. Weinstock MA. Epidemiology of mycosis fungoides. Semin Dermatol. 1994;13:154-159.

10. Myskowski PL. Cutaneous T-cell lymphoma and human immunodeficiency virus: the spectrum broadens. Arch Dermatol. 1991;127:1045-1047.

11. Pascual J, Torrelo A, Teruel JL, et al. Cutaneous T cell lymphomas after renal transplantation. Transplantation. 1992;53:1143-1145.

12. Kaufman D, Gordon LI, Variakojis D, et al. Successfully treated Hodgkin’s disease followed by mycosis fungoides: case report and review of the literature. Cutis. 1987;39:291-296.

13. Bazin PAE. Maladies de la Peau Observees a l’Hopital St. Louis. 1876.

14. Videl E, Brocq L. Etude sur le mycosis fungoides. Fr Med. 1885;14:518-530.

15. King-Ismael D, Ackerman AB. Guttate parapsoriasis/digitate dermatosis (small plaque parapsoriasis) is mycosis fungoides. Am J Dermatopathol. 1992;14:518-530.

16. Burg G, Dummer R. Small plaque (digitate) parapsoriasis is an "abortive cutaneous T-cell lymphoma" and is not mycosis fungoides. Arch Dermatol. 1995;131:336-338.

17. Ackerman AB. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an "abortive" one, it must be mycosis fungoides! Arch Dermatol. 1996;132:562-566.

18. Kurban RS, Safai B. Cutaneous T-cell lymphomas. In: Cancer of the Skin. Philadelphia, Pa: WB Saunders Co; 1991:319-331.

19. Dmitrovsky E, Matthews MJ, Bunn PA, et al. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol. 1987;5:208-215.

20. Greer JP, Salhany KE, Cousar JB, et al. Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. Hematol Oncol. 1990;8:215-227.

21. Cerroni L, Rieger E, Hodl S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol. 1992;16:543-552.

22. Kerl H, Hodl S, Smolle J, et al. Classification and prognosis of cutaneous T-cell lymphomas. Z Hautkr. 1986;61:63-67.

23. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol. 1980;2:89-106.

24. Weinstock MA, Horm JW. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer. 1988;62:1658-1661.

25. Duncan SC, Winkelmann RK. Circulating Sezary cells in hospitalised dermatology patients. Br J Dermatol. 1978;99:171-178.

26. Schechter GP, Sausville EA, Fischmann AB, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood. 1987;69:841-849.

27. Stolz W, Schmoeckel C, Burg G, et al. Circulating Sezary cells in the diagnosis of Sezary syndrome (quantitative and morphometric analyses). J Invest Dermatol. 1983;81:314-319.

28. Winkelmann RK, Buechner SA, Diaz-Perez JL. Pre-Sezary syndrome. J Am Acad Dermatol. 1984;10:992-999.

29. Duncan SC, Winkelmann RK. Circulating Sezary cells in hospitalized dermatology patients. Br J Dermatol. 1978;99:171-178.

30. Heald P, Yan S, Edelson R. Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol. 1994;130:198-203.

31. Braverman IM, Yager NB, Chen M, et al. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol. 1987;16:45-60.

32. Bignon YJ, Roger H, Souteyrand P, et al. Study of T-cell antigen receptor gene rearrangement: A useful tool for early diagnosis of mycosis fungoides. Acta Derm Venereol (Stockh). 1989;69:217-222.

33. Berger CL, Eisenberg A, Soper L, et al. Dual genotype in cutaneous T cell lymphoma: immunoglobulin gene rearrangement in clonal T cell malignancy. J Invest Dermatol. 1988;90:73-77.

34. Weiss LM, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis: evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med. 1986;315:475-479.

35. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep. 1979;63:725-728.

36. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome: definition of three distinctive prognostic groups. Ann Intern Med. 1988;109:372-382.

37. Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol. 1985;16:1098-1109.

38. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784-1790.

39. Jorg B, Kerl H, Thiers BH, et al. Therapeutic approaches in cutaneous lymphoma. Dermatol Clin. 1994;12:433-441.

40. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol. 1986;14:1029-1038.

41. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20:416-428.

42. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19:684-691.

43. Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120:1585-1590.

44. Price NM, Deneau DG, Hoppe RT. The treatment of mycosis fungoides with ointment-based mechlorethamine. Arch Dermatol. 1982;118:234-237.

45. Hoppe RT, Abel EA, Deneau DG, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5:1796-1803.

46. Cummings J, MacLellan A, Langdon SJ, et al. The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLC. J Pharm Pharmacol. 1993;45:6-9.

47. Gilchrest BA, Parrish JA, Tanenbaum L, et al. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer. 1976;38:683-689.

48. Honigsmann H, Brenner W, Rauschmeier W, et al. Photochemotherapy for cutaneous T cell lymphoma: a follow-up study. J Am Acad Dermatol. 1984;10:238-245.

49. Powell FC, Spiegel GT, Muller SA. Treatment of parapsoriasis and mycosis fungoides: the role of psoralen and long-wave ultraviolet light (PUVA). Mayo Clin Proc. 1984;59:538-546.

50. Rosenbaum MM, Roenigk HH Jr, Caro WA, et al. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques: long-term follow-up in forty-three patients. J Am Acad Dermatol. 1985;13:613-622.

51. Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990;95(suppl 6):198S-205S.

52. Gupta AK, Anderson TF. Psoralen photochemotherapy. J Am Acad Dermatol. 1987;17:703-734.

53. Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol. 1997;36:183-185.

54. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePU) and PUVA in mycosis fungoides, plaque stage. Acta Derm Venereol (Stockh). 1989;69:536-538.

55. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep. 1979;63:691-700.

56. Hoppe RT. The management of mycosis fungoides at Stanford: standard and innovative treatment programmes. Leukemia. 1991;5(suppl):46-48.

57. Van Vloten WA, Vroome H, Noordijk EM. Total skin electron beam irradiation for cutaneous T-cell lymphoma. Br J Dermatol. 1985;112:697-702.

58. Lo TC, Salzman FA, Costey GE, et al. Megavolt electron irradiation for localized mycosis fungoides. Acta Radiol Oncol. 1981;20:71-74.

59. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med. 1987;316:297-303.

60. Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1990;23:898-902.

61. Zic J, Arzubiaga C, Salhany KE, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1992;27:729-736.

62. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol. 1992;27:427-433.

63. Ringenberg QS, Anderson PC. Interferons in the treatment of skin disease. Int J Dermatol. 1986;25:273-279.

64. Foon KA, Bunn PA Jr. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Semin Oncol. 1986;13:35-39.

65. Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alpha-2a in mycosis fungoides and Sezary syndrome. J Clin Oncol. 1990;8:155-160.

66. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986;57:1689-1695.

67. Savon A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80:587-592.

68. Bunn PA Jr, Hoffman SJ, Morris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Ann Intern Med. 1994;121:592-602.

69. Reintgen D, King J, Cox C. Computer database for melanoma registry: a clinical management and research tool to monitor outcomes and ensure continuous quality improvement. Surg Clin North Am. 1996;76:1273-1285.

Address reprint requests to Dr Glass at the Cutaneous Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr, Tampa, FL 33612

Back to Cancer Control Journal Volume 5 Number 1